← Back to Clinical Trials
Recruiting NCT06017687

NCT06017687 Data Collection and Evaluation of OptiBP Under Investigational Use

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06017687
Status Recruiting
Phase
Sponsor Biospectal
Condition General Population
Study Type INTERVENTIONAL
Enrollment 500,000 participants
Start Date 2023-09-28
Primary Completion 2024-09

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type INTERVENTIONAL
Interventions
OptiBP Study app

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 500,000 participants in total. It began in 2023-09-28 with a primary completion date of 2024-09.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The purpose of this study is to collect data to develop and evaluate the use of state-of-the-art machine learning approaches within a mobile phone application for the estimation of blood pressure.

Eligibility Criteria

Inclusion Criteria: 1. Be at least 18 years old (at least 19 years old in Alabama and Nebraska, at least 21 years old in Puerto Rico); 2. Live in the United States of America 3. Have an Android smartphone 4. Have access to an arm-worn blood pressure monitor (cuff) 5. Have access to the Google Play store to download the OptiBP study app on their phone 6. Be comfortable communicating in written and spoken English 7. Be willing and able to provide informed consent to participate in the study Exclusion Criteria: 1. Known contact dermatitis to nickel/chromium 2. Lesion or deficiency on hand, preventing placing a finger on the smartphone camera 3. Known dysrhythmia like bigeminy, trigeminy, isolated VPB, atrial fibrillation

Contact & Investigator

Central Contact

Frederic Frappereau

✉ study@biospectal.com

📞 650-229-8604

Principal Investigator

Frederic Frappereau

PRINCIPAL INVESTIGATOR

Biospectal

Frequently Asked Questions

Who can join the NCT06017687 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying General Population. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06017687 currently recruiting?

Yes, NCT06017687 is actively recruiting participants. Contact the research team at study@biospectal.com for enrollment information.

Where is the NCT06017687 trial being conducted?

This trial is being conducted at Truckee, United States.

Who is sponsoring the NCT06017687 clinical trial?

NCT06017687 is sponsored by Biospectal. The principal investigator is Frederic Frappereau at Biospectal. The trial plans to enroll 500,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: July 2026  ·  Data Methodology